Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 10 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)CompletedNCT04198415
- Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
- A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical PracticeCompletedNCT04178317
- Study of LUCAR-20S in Patients With R/R NHLTerminatedNCT04176913Phase 1
- Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
- Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantActive, not recruitingNCT04167683
- A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in GreeceActive, not recruitingNCT04159779
- CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesStatus unknownNCT04156243Early Phase 1
- CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell MalignanciesStatus unknownNCT04156178Early Phase 1
- Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLCompletedNCT04155710Phase 1
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
- Immunotherapy With CD19 CAR T-cells for B-Cell LeukemiaStatus unknownNCT04100187Phase 1
- Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeStatus unknownNCT04094051
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesActive, not recruitingNCT04072458Phase 1
- A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based AssessmentStatus unknownNCT04059081Phase 2
- ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
- Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
- A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic LeukemiaCompletedNCT04016636
- ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and LymphomaStatus unknownNCT04014894Phase 1
- Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaActive, not recruitingNCT04007029Phase 1
- Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic LeukemiaStatus unknownNCT03971565
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruitingNCT03960840Phase 1/2
- Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceWithdrawnNCT03943342Phase 2
- Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.CompletedNCT03939234Phase 2
- A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesActive, not recruitingNCT03913949Phase 1
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT03900598Phase 1
- ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and LymphomaStatus unknownNCT03895944Early Phase 1
- A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasTerminatedNCT03893682Phase 1
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
- Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK InhibitorWithdrawnNCT03884972Phase 1
- Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell MalignanciesStatus unknownNCT03881774Phase 1
- Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their EffectivenessStatus unknownNCT03881592
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian FederationCompletedNCT03873857
- Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple MyelomaCompletedNCT03870633
- Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic LeukemiaStatus unknownNCT03847727
- An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)Active, not recruitingNCT03824483Phase 2
- Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaStatus unknownNCT03823365Phase 1
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
- A Phase I Study of YY-20394 in Patients With B Cell Hematologic MalignanciesStatus unknownNCT03757000Phase 1
- Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLCompletedNCT03739554Phase 1
- Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 DysfunctionActive, not recruitingNCT03734198Phase 2
- A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World SettingCompletedNCT03720561
- Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLTerminatedNCT03708003Phase 2
- Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic LeukemiaActive, not recruitingNCT03701282Phase 3
- CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCTStatus unknownNCT03685786Phase 1
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedNCT03671590Phase 1
- A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeSuspendedNCT03659669
- Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLLWithdrawnNCT03639324Phase 1
- Observational Study of Ibrutinib Use in CLLStatus unknownNCT03633045
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruitingNCT03625037Phase 1/2
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
- Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesStatus unknownNCT03588598Phase 1
- Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandCompletedNCT03582098
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLTerminatedNCT03547115Phase 1
- Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC StudyCompletedNCT03545035
- The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With IbrutinibCompletedNCT03528941
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
- Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsActive, not recruitingNCT03513562Phase 2
- Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLLCompletedNCT03502876
- Chronic Lymphocytic Leukemia Responds to Dermal ChelationStatus unknownNCT03495492Not applicable
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1
- Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaCompletedNCT03476655
- Autoimmune Cytopenia and BcR InhibitorsStatus unknownNCT03469895
- A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLActive, not recruitingNCT03467867Phase 2
- A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory LeukemiaStatus unknownNCT03463928Phase 1
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- A Study of BNC105P Combined With IbrutinibCompletedNCT03454165Phase 1
- Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT03447808Phase 1
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
- A Prognostic Tool for Early Stage CLLCompletedNCT03436524
- A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeCompletedNCT03425591
- Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent IbrutinibActive, not recruitingNCT03422393Phase 1
- Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?Status unknownNCT03417414
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
- A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT03398967Phase 1/2
- Association of CD49d and CD44 in CLL Patients and Their Role in PrognosisStatus unknownNCT03380299
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedNCT03379051Phase 1/2
- Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
- Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
- This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxWithdrawnNCT03343678Phase 1
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03331198Phase 1/2
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT03328273Phase 1
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
- Identification of Occupational Exposures in Acute Hematologic MalignancyCompletedNCT03316209
- Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeCompletedNCT03310190